SNDL Consolidates U.S. Medical Cannabis Operations with Parallel Asset Acquisition

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), the Canadian cannabis company, announced the successful completion of its acquisition of certain assets from Surterra Holdings, Inc. (Parallel), a U.S. vertically integrated cannabis operator. This strategic move positions SNDL, through its Sunstream Bancorp Inc. joint venture, as a significant player in the U.S. medical cannabis market, supporting its goal of becoming one of the first Nasdaq-listed companies with direct, consolidated U.S. medical cannabis operations.

The acquisition was executed through a consensual secured creditor foreclosure of specified equity interests and assets, encompassing Parallel's licensed operations in Florida, Texas, and Massachusetts. Through its Sunstream Bancorp Inc. joint venture, SNDL will hold an indirect majority economic exposure equivalent to 66.7% of TransactionCo's equity and 69.4% of its debt, which includes the acquired assets. The transaction also resulted in the extinguishment of approximately $842 million of Parallel's debt obligations. The acquired assets comprise 56 retail locations and three cultivation and manufacturing facilities across the three states, with an estimated annualized revenue of approximately $150 million.

The operational footprint includes 43 dispensaries in Florida operating under the Surterra Wellness brand, 10 retail or pickup locations in Texas under the Goodblend brand, and three dispensaries in Massachusetts under the New England Treatment Access brand. SNDL anticipates converting its indirect exposure into direct, consolidated holdings in the coming months, subject to legal, regulatory, accounting, and Nasdaq requirements. The company clarified that any adult-use or recreational cannabis exposure, including in Massachusetts, is expected to remain deconsolidated pending further regulatory and exchange approvals.

This acquisition reinforces SNDL's position within the North American cannabis industry while demonstrating a cautious approach to the complex U.S. regulatory landscape. Joint ventures like Sunstream Bancorp Inc. have been crucial tools for Canadian companies navigating the challenges posed by U.S. federal laws, which still classify cannabis as illegal. SNDL's acquisition of these assets via a secured creditor foreclosure, following Parallel's default on a $150 million loan from Talladega (an affiliate of Sunstream), exemplifies a strategic investment in the distressed asset market.

Market analysts anticipate positive long-term impacts on SNDL's income statement and balance sheet from this move. Should direct consolidation occur, SNDL is expected to solidify its leading position in the U.S. medical cannabis market and enhance operational efficiencies. In the short term, the acquisition does not have an immediate impact on SNDL's financial reporting, apart from the purchase of a $29.75 million principal loan position at a 25% discount. The investment will continue to be accounted for using the equity method under International Financial Reporting Standards.